[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C@H1][C@H1][Branch2][=N][=C][C@@][Branch2][=N][=Branch1][C][C@@H1][Branch1][Ring2][O][Ring1][=Branch1][O][C@@H1][C@H1][Branch2][N][Branch2][C@@H1][Branch2][N][Ring1][C@H1][Branch2][O][=N][O][C@H1][Ring1][=Branch1][O][C][=C][C][=C][C][=C][Ring1][=Branch1][O][C][=C][Branch2][#Branch2][=Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C@H1][Branch2][=Branch2][N][C@H1][Branch2][Branch2][Branch2][C][=Branch1][C][=O][N][C@H1][Branch2][#Branch1][=Branch2][C][=Branch1][C][=O][N][C@H1][Ring2][Ring1][Ring2][C][=Branch1][C][=O][N][C@@H1][C][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][Branch1][O][C][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][O][O][C@H1][Branch2][Ring2][=Branch1][N][C][=Branch1][C][=O][C@H1][Branch2][Ring1][#Branch1][C@@H1][Branch2][Ring1][C][C][=C][C][=Branch1][N][=C][Branch1][Branch1][O][Ring2][Branch1][Ring2][C][=C][Ring1][#Branch1][Cl][O][N][C][Ring2][Ring1][P][=O][C][=Branch1][C][=O][O][C][C][=Branch1][C][=O][N][N][C][=Branch1][C][=O][C@@H1][Branch1][#Branch1][C][C][Branch1][C][C][C][N][C][O][Cl][C][O][O][O][Branch1][C][C][N][O]"}, {"from": "gpt", "value": "The molecule is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.  As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196]."}]